Loading Events

Theravance Biopharma KOL Event to Discuss Ampreloxetine’s Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

DATE: May 23, 2024
TIME: 10:00 AM EDT

About The Event

Join Theravance Biopharma for a virtual KOL event featuring Horacio Kaufmann, MD, FAAN (Felicia B. Axelrod Professor of Neurology and Professor of Medicine at New York University Grossman School of Medicine) and Italo Biaggioni, MD (Professor of Medicine and Pharmacology Director, Vanderbilt Autonomic Dysfunction Center), who will discuss the unmet need and current treatment landscape for MSA patients with symptomatic nOH.

The event will also feature presentations from the Company’s CEO, Rick Winningham, Senior VP of Development, Aine Miller, and Chief Business Officer, Rhonda Farnum and will focus on the Company’s clinical development program for ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor with the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms of nOH in MSA patients.

A live question and answer session will follow the formal presentations.